

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	L10V <small>91% seen:25,302</small> • I13V <small>1.70% seen:30,796</small> • I15V <small>91% seen:11,084</small> • G16E <small>100% seen:11,038</small> • E35D <small>99% seen:19,248</small> • M36I <small>99% seen:19,211</small> • R41K <small>99% seen:18,717</small> • L63V <small>10% seen:30,142</small> • H69K <small>10% seen:25,798</small> • V77V <small>1.42% seen:30,125</small> • L89M <small>100% seen:11,736</small>	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
PR comments		
Other		
<ul style="list-style-type: none">L10I/V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.		

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for PI.	

Drug resistance interpretation: RT

NRTI Mutations:

None

NNRTI Mutations:

None

RT Other Mutations:

K11Q 99%
seen:27,120 • K20R 99%
seen:19,172 • V35MT 1.71%
seen:8,621 • T39TA 1.71%
seen:8,622 • V60I 100%
seen:39,7 • K101KN 0.99%
seen:763 • D123N 100%
seen:777 • I135T 100%
seen:108 • K173A 100%
seen:1,439 • Q174K 99%
seen:1,433 • D177E 99%
seen:1,444 • G196GE 0.43%
seen:976 • T200A 99%
seen:746 • Q207AT 1.71%
seen:836 • R211S 99%
seen:411 • F214L 100%
seen:296 • V245Q 100%
seen:104 • D250E 99%
seen:96 • S251N 99%
seen:96 • A354S 100%
seen:387

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

Susceptible

zidovudine (AZT)

Susceptible

stavudine (D4T)

Susceptible

didanosine (DDI)

Susceptible

emtricitabine (FTC)

Susceptible

lamivudine (3TC)

Susceptible

tenofovir (TDF)

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

Susceptible

efavirenz (EFV)

Susceptible

etravirine (ETR)

Susceptible

nevirapine (NVP)

Susceptible

rilpivirine (RPV)

Susceptible

RT comments

Other

• K101N/A/T are uncommon non-polymorphic NNRTI-selected mutation of uncertain phenotypic and clinical significance.

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for NRTL.	
No drug resistance mutations were found for NNRTL.	

Drug resistance interpretation: IN		HIVDB 9.5.1 (2023-11-05)
INSTI Major Mutations:	None	
INSTI Accessory Mutations:	None	
IN Other Mutations:	K7R <small>100% seen:1,238</small> • K14R <small>99% seen:1,808</small> • V31I <small>99% seen:2,708</small> • L45Q <small>99% seen:1,708</small> • L101I <small>100% seen:12,915</small> • T112V <small>100% seen:11,022</small> • T124A <small>100% seen:12,364</small> • T125A <small>100% seen:12,364</small> • I135V <small>100% seen:12,917</small> • K136Q <small>99% seen:1,917</small> • D167E <small>99% seen:2,394</small> • V201I <small>100% seen:1,714</small> • T218S <small>100% seen:358</small> • K219N <small>100% seen:361</small> • N222K <small>100% seen:361</small> • L234I <small>99% seen:361</small> • S283G <small>100% seen:917</small> • Q285QR <small>0.17% seen:904</small> R.105A	
Integrase Strand Transfer Inhibitors		
bictegravir (BIC)	Susceptible	
cabotegravir (CAB)	Susceptible	
dolutegravir (DTG)	Susceptible	
elvitegravir (EVG)	Susceptible	
raltegravir (RAL)	Susceptible	
Mutation scoring: IN		HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for INSTI.		